CTOs on the Move

Ivenix

www.ivenix.com

 
Ivenix, Inc. is a venture-backed medical device company with a vision to transform infusion delivery in every care setting, globally. The company is focused on bringing its first product to market, a new and innovative infusion management system for hospitals. The system combines integrated state-of-the-art information technology and simplicity with an adaptive fluid delivery platform that continuously measures flow. The company is headquartered in Amesbury, Massachusetts.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.ivenix.com
  • 21 Water St
    Amesbury, MA USA 01913
  • Phone: 978.792.5000

Executives

Name Title Contact Details

Funding

Ivenix raised $42M on 09/01/2015

Similar Companies

The Scienomics Group

The Scienomics Group is a Greenwich, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Rural Wisconsin Health Cooperative

Rural Wisconsin Health Cooperative is a Sauk City, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Development International

Medical Development International is a Ponte Vedra Beach, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Blistex

Blistex Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Oak Brook, IL. To find more information about Blistex Inc., please visit www.blistex.com

Orbus Therapeutics

Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.